

Machine Preservation Trial

MP vs. CS in Kidney Transplantation in collaboration with Eurotransplant



Scientific Steering Committee

Principal Investigators

 Rutger J. Ploeg (Coord.)

 Jacques Pirenne

 Andreas Paul

Members

Cyril Moers (Secretary)

Hugo Maathuis (RPC Liaison)

Jaap Homan v/d Heide

Ernst van Heurn

Frank van Gelder

Jean-Paul Squifflet

Jürgen Treckmann

Massimo Malago

Central Trial Assistance

Eurotransplant

Bernard Cohen

Jacqueline Smits

Margitta van Kasterop-Kutz

Deutsche Stiftung

Organtransplantation

Günter Kirste

Heiner Smit

Regional Perfusion Centers

Groningen, The Netherlands

Henri Leuvenink

Leuven, Belgium

Frank van Gelder

Essen, Germany

Bogdan Napieralski

Sponsor

Organ Recovery Systems

Protocol Amendment # 006

Proposed by: RPC Essen / Univ. Münster **Date:** 24-04-2005

Title: *Kidneys of the older donor – Histology, immunohistochemistry and Western blotting for evaluation of kidney tissue damage during CS and MP*

Background and Aim

The aim of this amendment is to examine the tissue damages set by CS and by MP and to demonstrate if MP is able to reduce tissue damage or causes different problems.

Tissue damage as a result of storage in cold ischemia can only in part be demonstrated by conventional light microscopy. Expression of stress proteins such as HO-1 and HSP 70 as well as activated, phosphorylated signal transduction kinases (p-erk, p-act, c-jun) is increased by hypoxia. Such modified expression levels can be demonstrated quantitatively by Western blotting, while immunohistochemistry is capable of revealing their topochemical distribution. Preliminary research showed that correlations with clinical and prognostic parameters can be established. Additionally, apoptosis in resident renal cells shall be studied (TUNEL, X-IAP, activated caspases).

Method

From each kidney graft of donors older than 55 years two needle biopsies will be taken: one prior to the start of MP and one biopsy one hour following reperfusion, or immediately prior to closure (time should be noted). The responsible surgeon will obtain the biopsies and the perfusionist will store the biopsy and transport it to the respective RPC. Biopsies will be examined at the Institute of Pathology of the University of Münster at the end of the trial.

To be analyzed:

- ◆ *Expression of stress proteins such as HO-1 and HSP 70 as well as activated, phosphorylated signal transduction kinases (p-erk, p-act, c-jun): Western blotting and immunohistochemistry*
- ◆ *Apoptosis in resident renal cells (TUNEL, X-IAP, activated caspases)*

Tissue damage markers in MP kidneys and in a control group of CS kidneys will be compared and correlation to outcome will be analyzed.